Longitudinal analysis of complete blood count parameters in advanced-stage lung cancer patients
| Autor: | Eszter Czibula, Zsolt Szegedi, Lilla Reiniger, Judit Moldvay, Zsolt Megyesfalvi, Lívia Rojkó, Vanda Téglási, Zoltan Szallasi, Balazs Dome |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology Adult Male medicine.medical_specialty Lung Neoplasms complete blood count Advanced‐stage lung cancer medicine.medical_treatment Disease Malignancy lcsh:RC254-282 03 medical and health sciences organ metastases 0302 clinical medicine Internal medicine medicine Humans Longitudinal Studies Lung cancer Aged Neoplasm Staging Retrospective Studies Aged 80 and over medicine.diagnostic_test business.industry Complete blood count Cancer General Medicine Immunotherapy Original Articles Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Primary tumor Blood Cell Count 030104 developmental biology 030220 oncology & carcinogenesis Absolute neutrophil count Female Original Article business |
| Zdroj: | Thoracic Cancer Thoracic Cancer, Vol 11, Iss 11, Pp 3193-3204 (2020) |
| ISSN: | 1759-7714 |
| Popis: | Background Metastatic lung cancer is a debilitating disease, but with the advances in immunotherapy, therapeutic options have vastly increased. Numerous complete blood count parameters (CBC) have been described as easily accessible biomarkers that might predict response to immunotherapy. However, to date, no comprehensive study has been performed on the longitudinal changes of these parameters during cancer progression. Methods The clinicopathological variables and CBC parameters of 986 advanced stage lung cancer patients were retrospectively analyzed. Blood tests were performed as part of the routine checkup and the results were recorded at the time of the diagnosis of the primary tumor, the diagnosis of brain or bone metastases, and also during the last available follow‐up. Results In the experimental subcohort, 352 and 466 patients were diagnosed with brain and bone metastases, respectively. The control group consisted of 168 patients without clinically detectable or other distant organ metastases. In our longitudinal analyses, we found significantly decreasing absolute lymphocyte count (ALC: P In our longitudinal analyses, we found significantly decreasing ALC, and significantly increasing ANC levels in advanced‐stage lung cancer patients during disease progression. Interestingly, patients with brain metastases have descending‐ascending PLT trendlines, while patients with bone metastases exhibit ascending‐descending trendlines during disease progression. The current study might help to improve patient selection and treatment strategies for brain and bone metastatic lung cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |